Cordella system measures, records, and transfers pulmonary artery pressure data from a heart failure patient’s home to clinicians. Credit: Robina Weermeijer on Unsplash.

Digital health and medical technology company Endotronix has concluded the enrolment of patients for a trial to evaluate the safety and efficacy of the Cordellapulmonary artery (PA) sensor system.

Dubbed the PROACTIVE-HF, the pivotal trial is claimed to be the first global investigational device exemption (IDE) study for PA pressure-guided heart failure (HF) management.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company recruited more than 450 patients across the US, Ireland and Belgium for the PROACTIVE-HF, which is an open-label, single-arm, multi-centre clinical trial.

Mortality, HF hospitalisations, and device safety are the primary endpoints of the study.

Primary endpoint data from the study is expected to be reported in the first half of next year.

Endotronix will use the data from the trial to support its pre-market approval (PMA) application for the device in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Endotronix CEO and co-founder Harry Rowland said: “I would like to congratulate all our clinical partners on their tremendous effort to complete enrollment for PROACTIVE-HF.

“Their hard work and dedication are key to improving outcomes and expanding patient access, and we appreciate their continued commitment to this trial.”

The Cordella system is designed to measure, record and transfer data related to pulmonary artery pressure (PAP) from the patient’s home to clinicians for evaluation and proactive, patient-centred remote HF management.

Comprising seven subsystems, the system takes daily PAP readings at a patient’s home and transfers the data to a care provider for assessment.

The subsystems include Cordella Sensor, Cordella Delivery System, myCordella Patient Reader, Reader Dock, Cordella Calibration Equipment (CalEQ), myCordella hub and Cordella Data Analysis Platform (CDAP).